RT Journal Article
SR Electronic
T1 Costs of typhoid vaccination for international travelers from the United States
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.03.24309664
DO 10.1101/2024.07.03.24309664
A1 Joo, Heesoo
A1 Maskery, Brian A.
A1 Francois Watkins, Louise K.
A1 Park, Joohyun
A1 Angelo, Kristina M.
A1 Halsey, Eric S.
YR 2024
UL http://medrxiv.org/content/early/2024/07/04/2024.07.03.24309664.abstract
AB In the United States, typhoid vaccination is recommended for international travelers to areas with a recognized risk of typhoid exposure. Using MarketScan® Commercial Database from 2016 through 2022, we estimated typhoid vaccination costs by route (injectable vs. oral) and provider setting (clinic vs. pharmacy). Of 165,930 vaccinated individuals, 99,471 received injectable and 66,459 received oral typhoid vaccines, with 88% and 17% respectively administered at clinics. Average costs for injectable vaccination were $132.91 per person [95% confidence interval (CI): $132.68–$133.13], with clinic and pharmacy costs at $136.38 [95% CI: $136.14–$136.63], and $107.45 [95% CI: $107.13–$107.77] respectively. Oral vaccination costs averaged $81.23 per person [95% CI: $81.14–$81.33], encompassing $86.61 [95% CI: $86.13– $87.10] at clinics and $80.14 [95% CI: $80.09–$80.19] at pharmacies. Out-of-pocket costs comprised 21% and 33% of total costs for injectable and oral vaccinations. These findings may inform clinical decision-making to protect international travelers’ health.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:A Centers for Disease Control and Prevention reviewer determined that the project, which used only deidentified data, did not meet the regulatory definition of human subject research and did not need institutional board review.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data utilized for this study are accessible from a third-party source, Merative. Data availability is subject to restrictions as the data were utilized under license. Therefore, these data are not publicly accessible.